US CGM Market – Dexcom, Medtronic & Abbott – Medtronic's Return to Market & Updated Competitive Landscape

  • Public Equity
  • Healthcare
  • Global


Former VP at Senseonics Holdings Inc


  • Recent trends and developments in the CGM (continuous glucose monitoring) device market and strategies to penetrate type 1 and type 2 diabetes populations
  • Competitive landscape and product differentiation – Dexcom’s (NASDAQ: DXCM) G7, Medtronic’s (NYSE: MDT) MiniMed and Abott’s (NYSE: ABT) Freestyle Libre 3, including compatibility with pumps, usability and other features to meet changing patient demands
  • Quality control outlook for Medtronic's MiniMed device and expectations for a new sensor in 2024
  • Potential threats for CGM market disruption, including emerging players and increase of weight loss drug use for the type 2 population
  • Global CGM global market opportunity and successful go-to-market dynamics


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited